Doribax: increased dose for hospital-acquired pneumonia

The dose and duration of Doribax (doripenem) treatment recommended for patients with nosocomial pneumonia has been increased.

Hospital-acquired pneumonia occurs more frequently in patients on ventilators | SCIENCE PHOTO LIBRARY
Hospital-acquired pneumonia occurs more frequently in patients on ventilators | SCIENCE PHOTO LIBRARY
A study in 233 patients with late-onset ventilator-associated pneumonia (VAP) was stopped early when a 7-day course of doripenem (1g by intravenous infusion every 8 hours) failed to display non-inferiority to a 10-day course of imipenem/cilastatin (1g by intravenous infusion every 8 hours). Detailed analysis indicated that the short fixed duration of treatment with doripenem was insufficient and was a major contributing factor to the inferior outcome.

New dosing recommendations

Based on these results, in combination with data from additional phase I and II trials using a 1g dosing regimen and from the pivotal phase III studies that used the 500mg dose, the following recommendations have been made:

  • The usual treatment duration for nosocomial pneumonia (including VAP) should be 10–14 days, preferably 14 days in infections due to non-fermenting organisms (eg, Pseudomonas or Acinetobacter spp.).
  • A dose of 1g by intravenous infusion over four hours at 8-hourly intervals should be considered if the patient has creatinine clearance ≥150ml/min or if infection is due to non-fermenting organisms.
  • Caution should be exercised when choosing doripenem as treatment, taking into account the appropriateness of a carbapenem antibacterial based on severity of infection, prevalence of resistance to other suitable antibacterials and the risk of selecting for carbapenem-resistant bacteria.
  • Consideration should be used when giving concomitant aminoglycosides (for example, if co-infection with P. aeruginosa is suspected or proven).

View Doribax drug record

Further information: Janssen-Cilag Ltd

Follow MIMS on Twitter

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

MIMS app

Access the full drug database and quick-reference tables on the go

Find out more